J Carmel Egan, Vice President at Eli Lilly to Speak at 7th Modern Drug Discovery Summit Oct 2011

Monrovia, CA (PressExposure) August 30, 2011 -- J. Carmel Egan, Vice President of Project Management at Eli Lilly and Company, will give a plenary keynote presentation on "Managing a Mixed Portfolio: Making Key Decisions at the Science, Project, Resource, and Governance Level" at the 7th Modern Drug Discovery and Development Summit to be held in San Diego, CA on October 19-21, 2011 by GTC.

Carmel Egan will discuss:
• Managing diverse portfolios comprised of small chemical structures and a range of complex biomolecules
• Providing portfolio governance from discovery through commercialization, decision making and prioritization
• The factors involved in the reliable delivery of a blended portfolio comprised of 30%-40% biomolecules
• Lilly's approach to achieve improved patient outcomes
• Fully utilizing the external universe of talent and capabilities to optimally manage a complex portfolio

Johanna Carmel Egan was named vice president of project management for Lilly in March 2005. Prior to that, she had been vice president of manufacturing science and technology since 2001. She had been executive director of product development since July 2000. She is a member of the senior management council. Carmel was a recipient of the 1999/2000 Chairman's Ovation Award. Sponsored by Sidney Taurel chairman and chief executive officer the award is presented annually to a select number of leaders who demonstrate an exceptional ability to motivate and develop people.

The 7th Modern Drug Discovery and Development Summit will bring researchers, lab directors/managers, and industry executives the critical scientific, technology, and business coverage that they need. M3D will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development. Over 125 leading industrial and academic experts will present at this three-day summit and is comprised of a half day plenary keynote session and 4 full conferences. The M3D Summit includes the following conferences:

5th Biomarker Discovery and Development
5th Drug Design and Medicinal Chemistry
5th Advances in Stem Cell Discovery and Development
4th Protein Discovery & Therapeutics

For more information, please visit http://www.gtcbio.com

About GTCbio

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.

Press Release Source: http://PressExposure.com/PR/GTCbio.html

Press Release Submitted On: August 30, 2011 at 9:24 pm
This article has been viewed 83572 time(s).